skip navigation

S M L Text size

The NEI 40th Anniversary Symposia Series

SD-OCT and OFDI at 850 and 1050 nm for retinal imaging in glaucoma and AMD

Johannes F. de Boer

The emergence of Spectra/Fourier domain OCT with a ~100 fold improvement of the sensitivity over conventional time domain OCT technology has revolutionized retinal imaging, allowing 3D volumetric measurement of retinal morphology in a few seconds.

Two different but similar technologies (SD-OCT and OFDI) provide high speed imaging at a wavelength of 850 nm and 1050 nm, respectively. At 850 nm the contrast between retinal layers seems to be slightly better, favoring this wavelength for determination of the Retinal Nerve Fiber thickness for glaucoma diagnosis. The better penetration depth of 1050 nm into the deeper layers of the retina and the choroid seems to favor this wavelength for AMD, providing better information of the sub-retinal pigmented epithelium layer. Examples of minimum distance band thickness for glaucoma, and type 1 AMD before and after treatment with anti-VEGF therapy will be shown.


Johannes F. de Boer

Prof. Dr. Johannes F. de Boer
Head Complex Systems Group
Department Of Physics
Vu University, Amsterdam
The Netherlands

Head Imaging Group
Rotterdam Ophthalmic Institute, Rotterdam, The Netherlands
Email: JFDEBOER@FEW.VU.NL

Dr. de Boer graduated from the University of Amsterdam, the Netherlands, in 1995, obtaining his Ph.D. in experimental physics. He did a postdoctoral fellowship at the Academic Medical Center, Amsterdam, The Netherlands. In 1997 he moved to the Beckman Laser Institute, University of California at Irvine as an Academic Assistant Researcher and was promoted to Assistant Adjunct Professor, Dept. of Surgery, in 1998. Dr. de Boer joined the Wellman Laboratories of Photomedicine, Harvard Medical School in 2001 as an Assistant Professor and was promoted to Associate Professor, Harvard Medical School, in 2005. In 2008 Dr. de Boer moved back to the Netherlands, taking up a full professor position at the Physics Department, VU University, Amsterdam, and Head of the Imaging Group at the Rotterdam Ophthalmic Institute, Rotterdam. He is currently developing a Biomedical Photonics program at the VU University, Amsterdam.

Dr. de Boer has over 80 peer reviewed publications, and an H-index of 35. Since 2003 he serves as Topical Editor for biomedical optics for the journal Optics Letters.

Dr. de Boer's interests are primarily focused on the development of new optical diagnostic technologies and the translation of these technologies to clinical applications. Over the past 10 years he has made significant contributions to the field of Optical Coherence Tomography. He has led the development of Polarization Sensitive OCT (PS-OCT). This technology measures the depth resolved changes in the polarization state of light reflected from biological tissues, which allows depth resolved measurement of tissue birefringence. He was the first to measure the depth resolved human Retinal Nerve Fiber Layer (RNFL) birefringence in vivo. It was established that the RNFL birefringence in normal subjects depends on retinal location. He has played an important role in the development to clinical practice of Optical Doppler Tomography (ODT), and the combination of polarization sensitivity with flow sensitivity, allowing simultaneous imaging of blood flow and polarization properties of tissue. He has significantly contributed to a technological advance improving the sensitivity of OCT by 100 to 1000 - fold. This sensitivity improvement provides a paradigm shift from point sampling to comprehensive screening of large tissue volumes. After his first demonstration, video rate retinal imaging has become a commercial instrument widely adopted by the clinical ophthalmic community.



Department of Health and Human Services NIH, the National Institutes of Health USA.gov